Praj Industries Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/jz26u68p09v3awpy8lc1u360.pdf

Key Takeaways


Margin Drivers & Profitability

Joshipura: "We are no longer dependent on a single molecule in a single market. We are now multiple markets, multiple molecules, multiple solutions, multiple capabilities that we can get paid for."

Domestic Bioenergy: The Policy Overhang

Joshipura: "Difficult to answer it just now." [on when the feedstock freeze will be unfrozen]

International Expansion & Order Wins

Joshipura: "Usually, one would expect that you will get the full contract on day one, that's not the way Brazil works. So, they would like to go through the steps of first engineering, finish the engineering, and then get a firm grip on the overall project cost, and then move forward with the establishment of project."

GenX Facility & Capacity Build-Out


Technology & New Molecules

Joshipura: "What is sufficient for me to say right now is that this is a huge step forward towards an era of biopolymer, bioplastic manufacturing in the country using indigenous feedstocks and indigenous technology."

Order Book & FY25 Outlook

Joshipura: "Sorry to disappoint you we don't give revenue number guidance. When you talk revenue guidance, my CFO forget his mathematics, he is otherwise a brilliant guy, but he forgets."

Guidance & Commitments

CommitmentSpecificsTimeline
GenX revenue generationRevenue to begin from Mangalore facilityH2 FY25
GenX full potential70–80% of ₹2,000–2,500 cr revenue capacity~2 years from start of production
2G IOCL plant commissioningFull-scale commissioning targetedEnd of calendar year 2024
SAF project cost visibilityBetter view on project cost after engineering completion~6 months
Domestic SAF tractionMajor traction expected as CORSIA mandate nearsEnd of calendar year 2024
CBG blending mandateBecomes compulsory~18 months
FY25 CAPEX₹75–100 croresFY25
FY25 order bookingBetter than previous yearFY25
Input cost benefit durationContinues until old orders at higher material costs are executedNext few quarters
CBG large customer follow-on contractsCommitment expected from the conglomerateBeginning of next calendar year

Key Metrics

MetricQ1 FY25
Consolidated income from operations₹699 cr, vs ₹736 cr in Q1 FY24
EBITDA margin improvement291 bps YoY, on account of moderation in input cost and revenue composition
PBT before exceptional items₹78.88 cr, vs ₹77.7 cr in Q1 FY24
PBT after exceptional items₹107 cr, exceptional item pertains to sale of land
Profit after tax₹84.18 cr, vs ₹58.67 cr in Q1 FY24
Order intake₹888 cr, 58% from domestic market
Order backlog₹4,044 cr, 67% domestic orders as of June 30, 2024
Cash in hand₹830 cr as of June 30, 2024
Revenue mix72% Bioenergy, 20% Engineering, 8% PHS
Export revenue share23% of Q1 FY25 revenue, 24% increase YoY
Order intake mix52% Bioenergy, 38% Engineering, 10% PHS
Domestic order book from starchy feedstockOver 75%
Export component of order book42%
Slow-moving order book₹200–250 cr, less than 5% of total order book
FY25 CAPEX guidance₹75–100 cr